

Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

Oncomine Research Platform

RRID:SCR_007834

Type: Tool

Proper Citation

Oncomine Research Platform (RRID:SCR_007834)

Resource Information

URL: <http://www.oncomine.org>

Proper Citation: Oncomine Research Platform (RRID:SCR_007834)

Description: Oncomine Research Platform is a partially-commercial suite of products for online cancer gene expression analysis dedicated to the academic and non-profit research community. Oncomine combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data-mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation and prioritization. Oncomine was developed by physicians, scientists, and software engineers at the University of Michigan and is now fully supported for the academic and non-profit research community by Compendia Bioscience.

Synonyms: OncoMine

Resource Type: analysis service resource, data analysis service, production service resource, service resource

Keywords: FASEB list

Resource Name: Oncomine Research Platform

Resource ID: SCR_007834

Alternate IDs: nif-0000-03218, OMICS_00775, SCR_010949

Record Creation Time: 20220129T080244+0000

Record Last Update: 20260808T185901+0000

Ratings and Alerts

No rating or validation information has been found for Oncomine Research Platform.

No alerts have been found for Oncomine Research Platform.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4006 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Bai Y, et al. (2026) CCL chemokines as prognostic and immunotherapeutic markers in prostate cancer: a comprehensive analysis. World journal of surgical oncology, 24(1).

Suenaga M, et al. (2026) Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. ESMO gastrointestinal oncology, 12, 100323.

Mestareehi A, et al. (2026) Integrated Global Phosphoproteomic, Bioinformatic, and Machine Learning Analysis Reveals Regulatory Networks of TOP1, TOP2A, TOP2B, and C1orf35 in Hepatocellular Carcinoma (HCC). Oncology research, 34(5), 18.

Li S, et al. (2026) METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway. Cellular oncology (Dordrecht, Netherlands), 49(3).

He Y, et al. (2026) SHCBP1 Is Upregulated in Colon Adenocarcinoma and Promotes Tumor Cell Proliferation and Growth. Current oncology (Toronto, Ont.), 33(5).

Wang J, et al. (2026) GCAS: An Integrated R Package and Shiny App for Comprehensive Cancer Data Analysis. Biomolecules, 16(6).

Liu J, et al. (2026) GD3s-mediated lipid metabolism reprogramming promotes proliferation and metastasis of melanoma. Journal of translational medicine, 24(1).

Chen ZS, et al. (2026) AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma. International journal of medical sciences, 23(2), 695.

Liu P, et al. (2026) ANXA1 overexpression promotes B cell acute lymphoblastic leukemia progression and resistance by regulating fatty acid metabolism through PI3K/Akt signaling. Molecular and cellular biochemistry, 481(3), 1401.

Karapouliou C, et al. (2025) HMMR has oncoprotein-like properties in neuroblastoma cells and high HMMR expression has independent prognostic potential in neuroblastomas. Scientific reports, 15(1), 40434.

Wang W, et al. (2025) Unveiling the impact of C15orf48 on non-small cell lung cancer through NF-kappa B signaling. *Biomolecules & biomedicine*, 25(5), 1162.

Yang G, et al. (2025) NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer. *Journal of advanced research*, 72, 555.

Dong S, et al. (2025) The prognostic value of mitogen-activated protein kinase kinase in liver hepatocellular carcinoma by bioinformatics. *Medicine*, 104(26), e42933.

Uno K, et al. (2025) Implication of KLHL Gene Family Member KLHL5 in Colorectal Cancer Progression and Prognosis. *Cancer science*, 116(9), 2580.

Levine SR, et al. (2025) Report of the 2023 Mary Tyler Moore Vision Initiative Workshop. *Translational vision science & technology*, 14(7), 11.

Zeng JI, et al. (2025) IL1A: a novel prognostic biomarker and potential therapeutic target for renal clear cell carcinoma. *Oncology research*, 33(7), 1739.

Ding Z, et al. (2025) The expression and prognostic value of CCL19 in breast cancer. *Discover oncology*, 16(1), 830.

Shan H, et al. (2025) USP24 promotes hepatocellular carcinoma progression by deubiquitinating and stabilizing YAP1. *Cancer cell international*, 25(1), 164.

Wei J, et al. (2025) PlexinD1 is a driver and a therapeutic target in advanced prostate cancer. *EMBO molecular medicine*, 17(2), 336.

Qiu X, et al. (2025) TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma. *Applied immunohistochemistry & molecular morphology : AIMM*, 33(4), 242.